DBV Technologies Advances Peanut Allergy Treatment, Plans BLA Submission in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Should l Buy DBVT?
Source: Benzinga
- Clinical Breakthrough: DBV Technologies announced positive topline results from the Phase 3 VITESSE trial of its VIASKIN® Peanut patch in December 2025, achieving a significant treatment effect with 46.6% responders compared to 14.8% in the placebo group, marking a major advancement in peanut allergy treatment.
- Accelerated Regulatory Path: The trial's success has led to alignment with the FDA on safety data, with plans for a Biologics License Application (BLA) submission in H1 2026, providing a safe and convenient non-invasive treatment option for peanut allergy patients, addressing a critical market need.
- Financial Performance: Despite generating $2.38 million in revenue last quarter, DBV reported a loss of $28.44 million, indicating the need for improved financial health in the rapidly growing allergy treatment market, while its high valuation and debt levels raise investor concerns.
- Leadership Enhancements: Recent appointments of a new Chief Commercial Officer and board members strengthen DBV's execution capabilities to navigate regulatory milestones and prepare for a potential U.S. launch, showcasing the company's strong potential to transition from clinical success to commercial impact.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 46.40 USD with a low forecast of 40.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.460
Low
40.00
Averages
46.40
High
51.00
Current: 21.460
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Total Voting Rights and Shares as of January 31, 2026
- Total Shares: As of January 31, 2026, the company has a total of 274,852,082 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing activities.
- Total Voting Rights: The total voting rights on the same date amount to 274,852,082, reflecting transparency in the company's governance structure and ensuring equal voice for all shareholders in major decisions, thereby enhancing investor confidence.
- Net Voting Rights: The net voting rights stand at 274,792,237 shares, indicating that a small portion of shares lacks voting rights, which may affect the actual influence of shareholders in corporate governance.
- Compliance Information: This information complies with Article 223-16 of the French Financial Markets Authority (AMF) regulations, ensuring the company's adherence to disclosure requirements, which helps to build market trust in the company.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies has secured €166.7 million through the full exercise of ABSA and BS warrants, ensuring sufficient operational funding for the next 12 months to support the commercial readiness of the VIASKIN® Peanut patch.
- Equity Dilution Impact: The financing resulted in the issuance of 59,657,507 new shares, which is expected to dilute existing shareholders' ownership from 1% to 0.78%, impacting equity but providing necessary funding for future growth.
- Market Entry Plans: The proceeds will be utilized for a potential Biologics License Application (BLA) and the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new allergy treatment options for children aged 4 to 7, addressing significant market needs.
- Future Outlook: If all outstanding pre-funded warrants are exercised, total financing could reach approximately €284.5 million, further enhancing the company's competitive position in the food allergy treatment sector.
See More
Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
- M&A Surge: In 2025, small and mid-cap biopharma companies accounted for 57% of acquisitions by deal count, with 33 deals totaling $30.9 billion, indicating a significant recovery in market confidence despite a drop in median deal value from $516 million to $303 million.
- Shift in Investor Focus: Investor attention has shifted from GLP-1 obesity drugs to cancer and autoimmune disease treatments in 2025, particularly next-generation cell therapies, reflecting strong demand for innovative treatment options and potential growth opportunities in the biotech sector.
- Strong Clinical Data: Approximately $6 billion in acquisitions related to next-generation cell therapies occurred over the past six months, highlighting significant interest from big pharma in this niche, which could drive stock price increases for involved companies.
- Optimistic Outlook: Analysts expect increased M&A and strategic partnerships in 2026, particularly in immunology and rare diseases, with a lower interest rate environment improving funding conditions and further supporting the growth of biotech companies.
See More
Total Voting Rights and Shares as of January 31, 2026
- Total Shares: As of January 31, 2026, the company has a total of 274,852,082 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing activities.
- Total Voting Rights: The total voting rights on the same date amount to 274,852,082, reflecting transparency in the company's governance structure and ensuring equal voice for all shareholders in major decisions, thereby enhancing investor confidence.
- Net Voting Rights: The net voting rights stand at 274,792,237 shares, indicating that a small portion of shares lacks voting rights, which may affect the actual influence of shareholders in corporate governance.
- Compliance Information: This information complies with Article 223-16 of the French Financial Markets Authority (AMF) regulations, ensuring the company's adherence to disclosure requirements, which helps to build market trust in the company.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies has secured €166.7 million through the full exercise of ABSA and BS warrants, ensuring sufficient operational funding for the next 12 months to support the commercial readiness of the VIASKIN® Peanut patch.
- Equity Dilution Impact: The financing resulted in the issuance of 59,657,507 new shares, which is expected to dilute existing shareholders' ownership from 1% to 0.78%, impacting equity but providing necessary funding for future growth.
- Market Entry Plans: The proceeds will be utilized for a potential Biologics License Application (BLA) and the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new allergy treatment options for children aged 4 to 7, addressing significant market needs.
- Future Outlook: If all outstanding pre-funded warrants are exercised, total financing could reach approximately €284.5 million, further enhancing the company's competitive position in the food allergy treatment sector.
See More
Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
- M&A Surge: In 2025, small and mid-cap biopharma companies accounted for 57% of acquisitions by deal count, with 33 deals totaling $30.9 billion, indicating a significant recovery in market confidence despite a drop in median deal value from $516 million to $303 million.
- Shift in Investor Focus: Investor attention has shifted from GLP-1 obesity drugs to cancer and autoimmune disease treatments in 2025, particularly next-generation cell therapies, reflecting strong demand for innovative treatment options and potential growth opportunities in the biotech sector.
- Strong Clinical Data: Approximately $6 billion in acquisitions related to next-generation cell therapies occurred over the past six months, highlighting significant interest from big pharma in this niche, which could drive stock price increases for involved companies.
- Optimistic Outlook: Analysts expect increased M&A and strategic partnerships in 2026, particularly in immunology and rare diseases, with a lower interest rate environment improving funding conditions and further supporting the growth of biotech companies.
See More
